Learning from Cl-941 about pharmacokinetically guided dose escalation
- 1 January 1992
- journal article
- editorial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (8-9) , 1302-1304
- https://doi.org/10.1016/0959-8049(92)90503-t
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Phase I trial of the anthrapyrazole CI-941: Prospective evaluation of a pharmacokinetically guided dose-escalationEuropean Journal Of Cancer, 1992
- Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.Journal of Clinical Oncology, 1991
- Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.Journal of Clinical Oncology, 1991
- Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug DevelopmentJNCI Journal of the National Cancer Institute, 1990
- Pharmacology and Clinical Toxicity of 4'-Iodo-4'-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I TrialsJNCI Journal of the National Cancer Institute, 1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patientsCancer Chemotherapy and Pharmacology, 1989
- Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelinesEuropean Journal of Cancer and Clinical Oncology, 1987